 UTRECHT, The Netherlands and PHILADELPHIA, April 01, 2021 GLOBE NEWSWIRE -- LAVA Therapeutics N.V. Nasdaq: LVTX, a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers bsTCEs to transform cancer therapy, today announced that Karen J. Wilson has been appointed to its Board of Directors and as chair of its Audit Committee. Ms. Wilson brings more than three decades of finance and leadership experience in the life sciences industry. 